SESN

Sesen Bio (SESN)

Sesen Bio Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:SESN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2023/08/10	20:30	PR Newswire (US)	Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:SESN	Sesen Bio Inc
2023/03/07	02:41	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/03/07	02:35	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/03/04	01:07	Edgar (US Regulatory)	Sec Staff Action/letter (sec Staff)	NASDAQ:SESN	Sesen Bio Inc
2023/03/04	01:06	Edgar (US Regulatory)	Sec Staff Action/letter (sec Staff)	NASDAQ:SESN	Sesen Bio Inc
2023/03/03	02:07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/03/03	01:32	Business Wire	Sesen Bio Stockholders Approve Merger with Carisma Therapeutics	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22:08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22:03	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22:02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	22:00	Business Wire	Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results	NASDAQ:SESN	Sesen Bio Inc
2023/02/28	06:33	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/27	22:02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SESN	Sesen Bio Inc
2023/02/21	23:05	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/21	23:00	Business Wire	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22:18	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22:08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22:04	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	22:02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	07:06	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	06:46	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/17	06:42	Business Wire	Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting	NASDAQ:SESN	Sesen Bio Inc
2023/02/16	22:02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/16	22:00	Business Wire	Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger	NASDAQ:SESN	Sesen Bio Inc
2023/02/16	06:55	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:SESN	Sesen Bio Inc
2023/02/15	22:02	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/15	22:00	Business Wire	BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics	NASDAQ:SESN	Sesen Bio Inc
2023/02/15	06:40	Edgar (US Regulatory)	Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registered on a Form S-4 (s-4mef)	NASDAQ:SESN	Sesen Bio Inc
2023/02/14	23:08	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:SESN	Sesen Bio Inc
2023/02/14	22:00	Business Wire	Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger	NASDAQ:SESN	Sesen Bio Inc